Revision as of 16:52, 3 May 2024

Back to Top

Section editor
	Unfilled If you are interested in this role, please contact us at [email protected].

This page contains studies that were specific to pediatric populations. For the more general Ewing sarcoma page, follow this link.
Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the historical regimens page. If you still can't find it, please let us know so we can add it!

0 regimens on this page 0 variants on this page

Upfront therapy

COG AEWS1031 Regimen A

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Leavey et al. 2021 (COG AEWS1031)	2010-11-22 to 2016-01-04	Phase 3 (C)	COG AEWS1031 Regimen B	Did not meet co-primary endpoints of EFS/OS

Note: Regimen A is a standard 17-week regimen consisting of induction and continuation.

Induction

Chemotherapy, VDC portion (cycles 1, 3, 5)

Vincristine (Oncovin) by the following age- and weight-based criteria:
- 10 kg or more AND 12 months old or older: 1.5 mg/m² (maximum dose of 2 mg) IV push once per day on days 1 & 8
- Less than 10 kg OR younger than 12 months old: 0.05 mg/kg IV push once per day on days 1 & 8
Doxorubicin (Adriamycin) by the following age- and weight-based criteria:
- 10 kg or more AND 12 months old or older: 37.5 mg/m² IV push/infusion over 1 to 15 minutes once per day on days 1 & 2
- Less than 10 kg OR younger than 12 months old: 1.25 mg/kg IV push/infusion over 1 to 15 minutes once per day on days 1 & 2
  - Administer at a concentration not to exceed 2 mg/mL. Doxorubicin should be administered through the tubing of rapidly infusing solution of D5W or 0.9% NaCl, and it should not be infused into a large vein
Cyclophosphamide (Cytoxan) by the following age- and weight-based criteria:
- 10 kg or more AND 12 months old or older: 1200 mg/m² IV over 30 to 60 minutes once on day 1
- Less than 10 kg OR younger than 12 months old: 40 mg/kg IV over 30 to 60 minutes once on day 1
  - May be administered as undiluted drug (20 mg/mL, reconstitute with 0.9% NaCl to avoid hypotonic solution) or further diluted

Supportive therapy, VDC portion (cycles 1, 3, 5)

Mesna (Mesnex) by the following age- and weight-based criteria:
- 10 kg or more AND 12 months old or older: 720 mg/m² IV infusion or IV/PO with cyclophosphamide once on day 1
- Less than 10 kg OR younger than 12 months old: 24 mg/kg IV infusion or IV/PO with cyclophosphamide once on day 1

Chemotherapy, IE portion (cycles 2, 4, 6)

Ifosfamide (Ifex) by the following age- and weight-based criteria:
- 10 kg or more AND 12 months old or older: 1800 mg/m² IV over 60 minutes once per day on days 1 to 5
- Less than 10 kg OR younger than 12 months old: 60 mg/kg IV over 60 minutes once per day on days 1 to 5
  - Achieve urine specific gravity less than or equal to 1.010 before starting ifosfamide.
Etoposide (Vepesid) by the following age- and weight-based criteria:
- 10 kg or more AND 12 months old or older: 100 mg/m² IV over 1 to 2 hours once per day on days 1 to 5
- Less than 10 kg OR younger than 12 months old: 3.3 mg/kg IV over 1 to 2 hours once per day on days 1 to 5

Supportive therapy, IE portion (cycles 2, 4, 6)

Mesna (Mesnex) by the following age- and weight-based criteria:
- 10 kg or more AND 12 months old or older: 1080 mg/m² IV infusion or IV/PO with ifosfamide once per day on days 1 to 5
- Less than 10 kg OR younger than 12 months old: 36 mg/kg IV infusion or IV/PO with ifosfamide once per day on days 1 to 5

14-day cycle for 6 cycles, followed by continuation (to be completed):

References

COG AEWS1031: Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021 Dec 20;39(36):4029-4038. Epub 2021 Oct 15. Erratum in: J Clin Oncol. 2022 Jul 20;40(21):2393. link to original article link to PMC article PubMed NCT01231906

@@ Line 1: / Line 1: @@
-{{#lst:Section editor transclusions|peds-sarcoma}}
+<span id="BackToTop"></span>
+<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
+[[#top|Back to Top]]
+</div>
+{{#lst:Editorial board transclusions|peds-sarcoma}}
+<big>''This page contains studies that were specific to pediatric populations. For the more general Ewing sarcoma page, follow [[Ewing sarcoma|this link]].</big>
+<br>''Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the [[Ewing_sarcoma,_pediatric_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
-|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
-<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 |}
 {{TOC limit|limit=4}}
+=Upfront therapy=
-=Upfront Therapy=
+==COG AEWS1031 Regimen A==
-==COGAEWS0031 Protocol==
+<div class="toccolours" style="background-color:#c8a2c8">
-===Regimen A Induction===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
-====Cycles 1 & 3 (VDC)====
+!style="width: 20%"|Study
-*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> IV push once on day 1 (maximum dose of 2 mg)
+!style="width: 20%"|Dates of enrollment
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV infusion over 48 hours once on day 1
+!style="width: 20%"|Comparator
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV over 1 hour on Days 1
+|-
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
+|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8677904/ Leavey et al. 2021 (COG AEWS1031)]
-*[[Mesna (Mesnex)]] 720 mg/m<sup>2</sup> IV continuous infusion on day 1
+|2010-11-22 to 2016-01-04
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Cyclophosphamide (Cytoxan)]] m<sup>2</sup>
+| style="background-color:#1a9851" |Phase 3 (C)
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Cyclophosphamide (Cytoxan)]] and remain until at least 8 hours after the end of the [[Cyclophosphamide (Cytoxan)]] infusion
+|[[#COG_AEWS1031_Regimen_B_999|COG AEWS1031 Regimen B]]
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 2
+| style="background-color:#ffffbf" |Did not meet co-primary endpoints of EFS/OS
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
+|-
+|}
-'''21 day cycle'''
+''Note: Regimen A is a standard 17-week regimen consisting of induction and continuation.''
+<div class="toccolours" style="background-color:#eeeeee">
-====Cycles 2 & 4 (IE)====
+===Induction===
-*[[Ifosfamide (Ifex)]] 1800 mg/m<sup>2</sup> IV infusion over 1 hour once on day 1 to 5
+<div class="toccolours" style="background-color:#b3e2cd">
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
+====Chemotherapy, VDC portion (cycles 1, 3, 5)====
-*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV infusion over 1 to 2 hours once on days 1 to 5
+*[[Vincristine (Oncovin)]] by the following age- and weight-based criteria:
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
+**10 kg or more AND 12 months old or older: 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV push once per day on days 1 & 8
-*[[Mesna (Mesnex)]] 1080 mg/m<sup>2</sup> IV continuous infusion on day 1
+**Less than 10 kg OR younger than 12 months old: 0.05 mg/kg IV push once per day on days 1 & 8
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Ifosfamide (Ifex)]] m<sup>2</sup>
+*[[Doxorubicin (Adriamycin)]] by the following age- and weight-based criteria:
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Ifosfamide (Ifex)]] and remain until at least 8 hours after the end of the [[Ifosfamide (Ifex)]] infusion
+**10 kg or more AND 12 months old or older: 37.5 mg/m<sup>2</sup> IV push/infusion over 1 to 15 minutes once per day on days 1 & 2
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 6
+**Less than 10 kg OR younger than 12 months old: 1.25 mg/kg IV push/infusion over 1 to 15 minutes once per day on days 1 & 2
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
+***Administer at a concentration not to exceed 2 mg/mL. Doxorubicin should be administered through the tubing of rapidly infusing solution of D5W or 0.9% NaCl, and it should not be infused into a large vein
+*[[Cyclophosphamide (Cytoxan)]] by the following age- and weight-based criteria:
-'''21 day cycle'''
+**10 kg or more AND 12 months old or older: 1200 mg/m<sup>2</sup> IV over 30 to 60 minutes once on day 1
+**Less than 10 kg OR younger than 12 months old: 40 mg/kg IV over 30 to 60 minutes once on day 1
-===Regimen A Continuation===
+***May be administered as undiluted drug (20 mg/mL, reconstitute with 0.9% NaCl to avoid hypotonic solution) or further diluted
-====Cycle 5 & 9 (VDC)====
+====Supportive therapy, VDC portion (cycles 1, 3, 5)====
- Cycle 5 begins on week 15 in patients receiving surgery week 13 (Regimen A<sub>1</sub>/A<sub>3</sub>)
+*[[Mesna (Mesnex)]] by the following age- and weight-based criteria:
+**10 kg or more AND 12 months old or older: 720 mg/m<sup>2</sup> IV infusion or IV/PO with cyclophosphamide once on day 1
-*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> IV push once on day 1 (maximum dose of 2 mg)
+**Less than 10 kg OR younger than 12 months old: 24 mg/kg IV infusion or IV/PO with cyclophosphamide once on day 1
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
+====Chemotherapy, IE portion (cycles 2, 4, 6)====
-*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV infusion over 48 hours once on day 1
+*[[Ifosfamide (Ifex)]] by the following age- and weight-based criteria:
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
+**10 kg or more AND 12 months old or older: 1800 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 5
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV over 1 hour on Days 1
+**Less than 10 kg OR younger than 12 months old: 60 mg/kg IV over 60 minutes once per day on days 1 to 5
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
+***Achieve urine specific gravity less than or equal to 1.010 before starting ifosfamide.
-*[[Mesna (Mesnex)]] 720 mg/m<sup>2</sup> IV continuous infusion on day 1
+*[[Etoposide (Vepesid)]] by the following age- and weight-based criteria:
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Cyclophosphamide (Cytoxan)]] m<sup>2</sup>
+**10 kg or more AND 12 months old or older: 100 mg/m<sup>2</sup> IV over 1 to 2 hours once per day on days 1 to 5
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Cyclophosphamide (Cytoxan)]] and remain until at least 8 hours after the end of the [[Cyclophosphamide (Cytoxan)]] infusion
+**Less than 10 kg OR younger than 12 months old: 3.3 mg/kg IV over 1 to 2 hours once per day on days 1 to 5
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 2
+====Supportive therapy, IE portion (cycles 2, 4, 6)====
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
+*[[Mesna (Mesnex)]] by the following age- and weight-based criteria:
+**10 kg or more AND 12 months old or older: 1080 mg/m<sup>2</sup> IV infusion or IV/PO with ifosfamide once per day on days 1 to 5
-'''21 day cycle'''
+**Less than 10 kg OR younger than 12 months old: 36 mg/kg IV infusion or IV/PO with ifosfamide once per day on days 1 to 5
+'''14-day cycle for 6 cycles, followed by continuation (to be completed):'''
-====Cycle 6, 8, 10, 12, & 14 (IE)====
+</div></div></div>
-*[[Ifosfamide (Ifex)]] 1800 mg/m<sup>2</sup> IV infusion over 1 hour once on day 1 to 5
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV infusion over 1 to 2 hours once on days 1 to 5
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Mesna (Mesnex)]] 1080 mg/m<sup>2</sup> IV continuous infusion on day 1
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Ifosfamide (Ifex)]] m<sup>2</sup>
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Ifosfamide (Ifex)]] and remain until at least 8 hours after the end of the [[Ifosfamide (Ifex)]] infusion
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 6
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
-'''21 day cycle'''
-====Cycle 7 (VDC) Regimen A<sub>1</sub> (Surgery Only)====
-*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> IV push once on day 1 (maximum dose of 2 mg)
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV infusion over 48 hours once on day 1
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV over 1 hour on Days 1
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Mesna (Mesnex)]] 720 mg/m<sup>2</sup> IV continuous infusion on day 1
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Cyclophosphamide (Cytoxan)]] m<sup>2</sup>
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Cyclophosphamide (Cytoxan)]] and remain until at least 8 hours after the end of the [[Cyclophosphamide (Cytoxan)]] infusion
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 2
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
-'''21 day cycle'''
-====Cycle 7 (VC) Regimen A<sub>2</sub> & A<sub>3</sub> (Radiation w/ or w/o Surgery)====
-*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> IV push once on day 1 (maximum dose of 2 mg)
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV over 1 hour on Days 1
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Mesna (Mesnex)]] 720 mg/m<sup>2</sup> IV continuous infusion on day 1
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Cyclophosphamide (Cytoxan)]] m<sup>2</sup>
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Cyclophosphamide (Cytoxan)]] and remain until at least 8 hours after the end of the [[Cyclophosphamide (Cytoxan)]] infusion
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 2
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
-'''21 day cycle'''
-====Cycle 11 (VC) Regimen A<sub>1</sub> (Surgery Only)====
-*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> IV push once on day 1 (maximum dose of 2 mg)
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV over 1 hour on Days 1
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Mesna (Mesnex)]] 720 mg/m<sup>2</sup> IV continuous infusion on day 1
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Cyclophosphamide (Cytoxan)]] m<sup>2</sup>
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Cyclophosphamide (Cytoxan)]] and remain until at least 8 hours after the end of the [[Cyclophosphamide (Cytoxan)]] infusion
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 2
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
-'''21 day cycle'''
-====Cycle 11 (VDC) Regimen A<sub>2</sub> & A<sub>3</sub> (Radiation w/ or w/o Surgery)====
-*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> IV push once on day 1 (maximum dose of 2 mg)
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV infusion over 48 hours once on day 1
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV over 1 hour on Days 1
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Mesna (Mesnex)]] 720 mg/m<sup>2</sup> IV continuous infusion on day 1
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Cyclophosphamide (Cytoxan)]] m<sup>2</sup>
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Cyclophosphamide (Cytoxan)]] and remain until at least 8 hours after the end of the [[Cyclophosphamide (Cytoxan)]] infusion
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 2
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
-'''21 day cycle'''
-====Cycle 13 (VC)====
-*[[Vincristine (Oncovin)]] 2 mg/m<sup>2</sup> IV push once on day 1 (maximum dose of 2 mg)
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV over 1 hour on Days 1
-**Treat with 50% doses calculated on a m<sup>2</sup> basis for children < 1 year, then consider increasing to 75% and then to 100 % of calculated dose if tolerated
-*[[Mesna (Mesnex)]] 720 mg/m<sup>2</sup> IV continuous infusion on day 1
-**NOTE: Protocol states that [[Mesna (Mesnex)]] should be dosed as AT LEAST 60% of [[Cyclophosphamide (Cytoxan)]] m<sup>2</sup>
-**[[Mesna (Mesnex)]] continuous infusion should be started at the same time as the [[Cyclophosphamide (Cytoxan)]] and remain until at least 8 hours after the end of the [[Cyclophosphamide (Cytoxan)]] infusion
-*[[Filgrastim (Neupogen)]] 5 mcg/kg SC for at least 7 days, or until ANC ≥ 750/μl, beginning on day 2
-**ANC ≥ 750/μl on or before day 7 of the cycle is not sufficient for discontinuing G-CSF
-'''21 day cycle'''
 ===References===
-#'''COG AEWS0031:''' Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, and Weiss AR.  Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2012 Nov 20;30(33):4148-4154. [https://dx.doi.org/10.1200%2FJCO.2011.41.5703 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494838/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23091096/ PubMed] NCT00006734
+#'''COG AEWS1031:''' Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021 Dec 20;39(36):4029-4038. Epub 2021 Oct 15. Erratum in: J Clin Oncol. 2022 Jul 20;40(21):2393. [https://doi.org/10.1200/jco.21.00358 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8677904/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34652968/ PubMed] [https://clinicaltrials.gov/study/NCT01231906 NCT01231906]
+[[Category:Ewing sarcoma regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Bone sarcomas]]
 [[Category:Pediatric solid tumors]]

Difference between revisions of "Ewing sarcoma, pediatric"